3
Clinical Trials associated with Donor Alloantigen Reactive Tregs(Rho Federal Systems Division)A Phase I, Open-Label, Multicenter Trial Exploring the Safety and Tolerability of Autologous Polyclonal Regulatory T Cell Therapy in Adults With Active Pemphigus (APG01)
T cells, a type of white blood cell called a lymphocyte, play an important role in the immune system. One subtype, the regulatory T cell (Treg) helps to regulate the immune system and may provide protection against the development of autoimmune disease. The hope is that these naturally occurring Treg cells can be utilized for the treatment of autoimmune disease and potentially replace the use of chronic immunosuppressive therapies that are associated with multiple side effects. There has been a small study showing safe administration of Tregs with decreased disease activity in patients with insulin-dependent diabetes. Tregs are being studied in lupus, cancer and organ transplantation.
This phase I trial will be conducted as an open-label, dose-escalation, multicenter trial in adult participants with active pemphigus.The purpose of this study is to test the safety and effect of Treg therapy in participants who have skin (cutaneous) involvement due to pemphigus.
Safety of Donor Alloantigen Reactive Tregs to Facilitate Minimization and/or Discontinuation of Immunosuppression in Adult Liver Transplant Recipients (CTOTC-12)
This research study is for liver transplant recipients and their respective living donors.
The purpose of this study is:
To see if it is safe for liver recipients to receive one dose of donor reactive T regulatory cells (Tregs)
To see if the Tregs allows a liver recipient to take less, or completely stop medications normally taken after receiving an organ transplant.
Donor-Alloantigen-Reactive Regulatory T Cell (darTreg) Therapy in Liver Transplantation (RTB-002)
The purpose of this study is look at the safety of:
Taking a specific combination of immunosuppressant drugs after liver transplantation
Receiving one of three different doses of donor-alloantigen-reactive regulatory T cells (darTregs) while taking this specific combination of drugs
100 Clinical Results associated with Donor Alloantigen Reactive Tregs(Rho Federal Systems Division)
100 Translational Medicine associated with Donor Alloantigen Reactive Tregs(Rho Federal Systems Division)
100 Patents (Medical) associated with Donor Alloantigen Reactive Tregs(Rho Federal Systems Division)
100 Deals associated with Donor Alloantigen Reactive Tregs(Rho Federal Systems Division)